- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- Mylan launches generic version of Detrol LA
- Lipitor may be the first statin to switch to OTC
- CVS Caremark to stop selling tobacco in all store locations
- Bloomberg: Greg Wasson joins thought leaders to discuss the state of health care in the United States
NEW YORK — According to a Bloomberg report published Friday morning, Abbott Laboratories, Johnson & Johnson and Sanofi are all potential suitors for Bausch & Lomb's eye care business in a deal that could be valued as high as $10 billion.
B&L is being shopped by private equity firm Warburg Pincus, which is working with Goldman Sachs Group, Bloomberg reported, and both Abbott and Sanofi have contracted financial advisors as well.
Other companies who have been invited to bid include Merck and Pfizer.
For the full story, click here.
Find us on Facebook for more information on drug store news, insights and products.